Protalix Biotherapeutics Inc (PLX)
$2.59
$0.49
(23.33%)
As on 28-Aug-2026 10:41EDT
Market cap
$192 Mln
Revenue (TTM)
$81 Mln
P/E Ratio
10.3
P/B Ratio
2.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-3 Mln
-
ROE
0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$0.2
-
Face value
--
-
Shares outstanding
80,571,642
10 Years Aggregate
CFO
$-185.47 Mln
EBITDA
$-158.82 Mln
Net Profit
$-194.74 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
| 43.9 | -- | 23.3 | 61.9 | 10.3 | 10.1 | -8.2 |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
| -4.3 | 5.6 | 29.9 | 64.7 | -77.1 | 10.7 | 5.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
2.6 | 191.8 | 80.6 | 19.0 | 30.7 | 31.7 | 10.3 | 2.7 |
| 85.4 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 248.4 | 16,614.0 | 1,054.4 | 755.9 | 5.7 | -- | 19.4 | 10.1 | |
| 73.9 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 105.5 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 537.3 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 603.8 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 351.6 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 146.8 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout Protalix Biotherapeutics Inc (PLX)
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides... Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey. Read more
-
President, CEO & Director
Mr. Dror Bashan
-
President, CEO & Director
Mr. Dror Bashan
-
Headquarters
Hackensack, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Protalix Biotherapeutics Inc (PLX)
What is the current share price of Protalix Biotherapeutics Inc (PLX) Today?
The share price of Protalix Biotherapeutics Inc (PLX) is $2.59 (NYSE) as of 28-Aug-2026 10:41 EDT. Protalix Biotherapeutics Inc (PLX) has given a return of 10.3% in the last 3 years.
What is the current PB & PE ratio of Protalix Biotherapeutics Inc (PLX)?
The P/E ratio of Protalix Biotherapeutics Inc (PLX) is 10.35 times as on 21-Aug-2026.
The P/B ratio of Protalix Biotherapeutics Inc (PLX) is 2.65 times as on 21-Aug-2026, a 50 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-21.41 |
2.93 |
2024 |
51.97 |
3.53 |
2023 |
15.62 |
3.87 |
2022 |
-4.71 |
-6.61 |
2021 |
-1.37 |
-6.28 |
What is the 52 Week High and Low of Protalix Biotherapeutics Inc (PLX)?
The 52-week high and low of Protalix Biotherapeutics Inc (PLX) are Rs 3.19 and Rs 1.52 as of 28-Aug-2026.
What is the market cap of Protalix Biotherapeutics Inc (PLX)?
Protalix Biotherapeutics Inc (PLX) has a market capitalisation of $ 192 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Protalix Biotherapeutics Inc (PLX)?
Before investing in Protalix Biotherapeutics Inc (PLX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.